Siga Technologies Shares Outstanding 2006-2020 | SIGA

Siga Technologies shares outstanding from 2006 to 2020. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Siga Technologies Annual Shares Outstanding
(Millions of Shares)
2019 82
2018 83
2017 79
2016 57
2015 54
2014 53
2013 52
2012 52
2011 54
2010 45
2009 37
2008 35
2007 33
2006 28
2005 25
Siga Technologies Quarterly Shares Outstanding
(Millions of Shares)
2020-03-31 81
2019-12-31 82
2019-09-30 82
2019-06-30 82
2019-03-31 82
2018-12-31 83
2018-09-30 83
2018-06-30 81
2018-03-31 79
2017-12-31 79
2017-09-30 79
2017-06-30 79
2017-03-31 79
2016-12-31 57
2016-09-30 54
2016-06-30 54
2016-03-31 54
2015-12-31 54
2015-09-30 54
2015-06-30 54
2015-03-31 54
2014-12-31 53
2014-09-30 54
2014-06-30 53
2014-03-31 53
2013-12-31 52
2013-09-30 53
2013-06-30 52
2013-03-31 52
2012-12-31 52
2012-09-30 52
2012-06-30 52
2012-03-31 52
2011-12-31 54
2011-09-30 52
2011-06-30 55
2011-03-31 50
2010-12-31 45
2010-09-30 46
2010-06-30 44
2010-03-31 43
2009-12-31 37
2009-09-30 38
2009-06-30 37
2009-03-31 36
2008-12-31 35
2008-09-30 35
2008-06-30 35
2008-03-31 34
2007-12-31 33
2007-09-30 34
2007-06-30 41
2007-03-31 33
2006-12-31 28
2006-09-30 28
2006-06-30 27
2006-03-31 27
2005-12-31 25
2005-09-30 25
2005-06-30 25
2005-03-31 25
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.493B $0.027B
SIGA Technologies Inc. is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. With broad technology platforms in both vaccines and antibiotics, SIGA's product development programs emphasize the increasingly serious problem of drug resistant bacteria. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses, dengue virus, and the filoviruses.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $65.594B 37.23
Takeda Pharmaceutical (TAK) Japan $60.596B 10.62
Astellas Pharma (ALPMY) Japan $32.790B 16.38
Eisai (ESALY) Japan $22.308B 41.56
UCB SA (UCBJF) Belgium $17.894B 0.00
Merck (MKGAF) Germany $14.993B 19.66
Grifols, S.A (GRFS) Spain $12.898B 16.03
Catalent (CTLT) United States $11.912B 46.05
Neurocrine Biosciences (NBIX) United States $11.164B 51.60
Ionis Pharmaceuticals (IONS) United States $7.863B 41.81
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $7.573B 0.00
Orion OYJ (ORINY) Finland $7.459B 33.42
Jazz Pharmaceuticals (JAZZ) Ireland $6.573B 10.52
United Therapeutics (UTHR) United States $5.061B 9.59
Evotec AG (EVTCY) Germany $4.045B 65.24
Nektar Therapeutics (NKTR) United States $3.953B 0.00
ChemoCentryx (CCXI) United States $3.735B 0.00
Hypermarcas (HYPMY) Brazil $3.692B 11.23
Arrowhead Pharmaceuticals (ARWR) United States $3.368B 367.67
FibroGen (FGEN) United States $3.180B 0.00
PTC Therapeutics (PTCT) United States $3.137B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.642B 10.86
Sage Therapeutics (SAGE) United States $1.941B 0.00
Pacira BioSciences (PCRX) United States $1.875B 38.37
USANA Health Sciences (USNA) United States $1.768B 18.13
Xencor (XNCR) United States $1.767B 0.00
Corcept Therapeutics (CORT) United States $1.747B 17.32
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.726B 0.00
Heron Therapeutics (HRTX) United States $1.670B 0.00
Zogenix (ZGNX) United States $1.605B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.575B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.555B 11.90
Akebia Therapeutics (AKBA) United States $1.499B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.449B 15.61
Portola Pharmaceuticals (PTLA) United States $1.401B 0.00
Karyopharm Therapeutics (KPTI) United States $1.375B 0.00
Tilray (TLRY) Canada $1.295B 0.00
Translate Bio (TBIO) United States $1.273B 0.00
CLINIGEN GP (CLIGF) United Kingdom $1.224B 0.00
Esperion Therapeutics (ESPR) United States $1.131B 0.00
Indivior (INVVY) United States $1.069B 13.27
Enanta Pharmaceuticals (ENTA) United States $1.032B 46.07
Endo (ENDP) Ireland $0.898B 1.39
ImmunoGen (IMGN) United States $0.837B 0.00
Collegium Pharmaceutical (COLL) United States $0.796B 0.00
Molecular Templates (MTEM) United States $0.705B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.694B 0.00
Aerie Pharmaceuticals (AERI) United States $0.661B 0.00
Ardelyx (ARDX) United States $0.640B 0.00
Radius Health (RDUS) United States $0.618B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.542B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.538B 0.00
Harpoon Therapeutics (HARP) United States $0.515B 0.00
Innate Pharma SA (IPHYF) France $0.489B 0.00
Organogenesis Holdings (ORGO) United States $0.489B 0.00
Trillium Therapeutics (TRIL) Canada $0.477B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.467B 18.26
DURECT (DRRX) United States $0.467B 0.00
Flexion Therapeutics (FLXN) United States $0.449B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.446B 10.77
Calithera Biosciences (CALA) United States $0.409B 0.00
Ocular Therapeutix (OCUL) United States $0.376B 0.00
MEI Pharma (MEIP) United States $0.350B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.346B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.342B 0.00
TherapeuticsMD (TXMD) United States $0.318B 0.00
Concert Pharmaceuticals (CNCE) United States $0.305B 0.00
Lannett Co Inc (LCI) United States $0.303B 6.64
Avadel Pharmaceuticals (AVDL) Ireland $0.298B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.288B 0.00
CASI Pharmaceuticals (CASI) United States $0.272B 0.00
Rafael Holdings (RFL) United States $0.257B 0.00
Redhill Biopharma (RDHL) Israel $0.245B 0.00
OptiNose (OPTN) United States $0.213B 0.00
Xeris Pharmaceuticals (XERS) United States $0.201B 0.00
VAXART, INC (VXRT) United States $0.197B 0.00
PROFOUND MEDICL (PROF) Canada $0.196B 0.00
KalVista Pharmaceuticals (KALV) United States $0.194B 0.00
Taiwan Liposome (TLC) Taiwan $0.188B 0.00
Nature's Sunshine Products (NATR) United States $0.185B 24.33
IMV INC (IMV) Canada $0.184B 0.00
Jounce Therapeutics (JNCE) United States $0.184B 4.40
Matinas Biopharma Holdings (MTNB) United States $0.178B 0.00
Aquestive Therapeutics (AQST) United States $0.168B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.129B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.127B 0.00
Altimmune (ALT) United States $0.127B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.121B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.115B 0.00
Recro Pharma (REPH) United States $0.113B 0.00
Champions Oncology (CSBR) United States $0.109B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.101B 0.00
Sundial Growers (SNDL) Canada $0.094B 0.00
Heat Biologics (HTBX) United States $0.094B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.089B 0.00
CV Sciences (CVSI) United States $0.088B 0.00
Otonomy (OTIC) United States $0.081B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.078B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.077B 0.00
SCYNEXIS (SCYX) United States $0.076B 0.00
CTI BioPharma (CTIC) United States $0.076B 0.00
Hemispherx BioPharma (AIM) United States $0.073B 0.00
Onconova Therapeutics (ONTX) United States $0.068B 0.00
Nivalis Therapeutics (ALPN) United States $0.067B 0.00
Biomerica (BMRA) United States $0.064B 0.00
Iterum Therapeutics (ITRM) Ireland $0.062B 0.00
Aclaris Therapeutics (ACRS) United States $0.056B 0.00
RENEURON GP (RNUGF) United Kingdom $0.056B 0.00
MediWound (MDWD) Israel $0.054B 0.00
Infinity Pharmaceuticals (INFI) United States $0.053B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.050B 29.82
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.050B 0.00
Natural Alternatives (NAII) United States $0.049B 0.00
IsoRay (ISR) United States $0.048B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.048B 102.00
GTx (ONCT) United States $0.047B 0.00
Lipocine (LPCN) United States $0.044B 0.00
Forward Pharma (FWP) Denmark $0.041B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.040B 0.00
PolarityTE (PTE) United States $0.039B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.036B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.036B 0.00
ElectroCore (ECOR) United States $0.035B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.035B 0.00
Neos Therapeutics (NEOS) United States $0.034B 0.00
Mannatechorporated (MTEX) United States $0.031B 5.90
AgeX Therapeutics (AGE) United States $0.028B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.025B 0.00
Jaguar Animal Health (JAGX) United States $0.025B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.024B 0.00
India Globalization Capital (IGC) United States $0.024B 0.00
Bio-Path Holdings (BPTH) United States $0.020B 0.00
ProPhase Labs (PRPH) United States $0.020B 0.00
Novan (NOVN) United States $0.019B 0.00
Can-Fite Biopharma (CANF) Israel $0.018B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.016B 0.00
Regulus Therapeutics (RGLS) United States $0.015B 0.00
Flex Pharma (SLRX) United States $0.014B 0.00
Cyanotech (CYAN) United States $0.012B 0.00
China SXT Pharmaceuticals (SXTC) China $0.012B 0.00
Shineco (TYHT) China $0.012B 0.00
Vical (BBI) United States $0.011B 0.00
RXi Pharmaceuticals (PHIO) United States $0.010B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.010B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.007B 0.00
Midatech Pharma (MTP) United Kingdom $0.007B 0.00
HANCOCK JAFFE (HJLI) United States $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Addex Therapeutics (ADXN) Switzerland $0.000B 0.00
CannTrust Holdings (CTST) Canada $0.000B 0.00